Untitled

Yeter, Hasan Haci; Fettahoglu, Farabi; Yesiloglu, Ekin; Akcay, Omer Faruk; Korucu, Berfu; Bali, Musa; Derici, Ülver

doi:10.6002/ect.2019.0287

Cited by 3 publications

(6 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We confirmed findings from several previous studies that being a male recipient is a risk factor of PTE [4,15,28]. Male gender was the most important risk factor for PTE in our meta-analysis, with a RR of 1.61.…”

Section: Discussionsupporting

confidence: 91%

“…A total of 61 studies underwent full-length article review; 22 were excluded, as they did not include controls or report the outcome of interest. A total of 39 observational studies [4,6,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47], including 7,099 patients, finally met our inclusion criteria and were included in the meta-analysis. Figure 1 outlines our search methodology and selection process; the baseline characteristics of the included studies are summarized in Table 1.…”

Section: Resultsmentioning

confidence: 99%

“…The rising of Hct must be persistent over a period of 3 to 6 months and independent of other pathological conditions, such as polycythemia vera, tumors associated with increased erythropoetin (EPO), hypoxia, chronic obstructive pulmonary disease, and obstructive sleep apnea [2,3]. PTE is one of the more common post-transplant hematologic complications which affect 8-26% of kidney transplant (KT) recipients [4]. The prevalence varies from study to study because of the different levels of Hct used for diagnosis, length persistence of disease, and gender variation of Hct cut-off values [2,5].…”

Section: Introductionmentioning

confidence: 99%

“…Spontaneous remission occurs in less than 25% of the patients within 2 years from the onset, with a median time of 13 months [2,4,5]. Thus, early detection and prompt management are necessary.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Risk factors and outcomes of post‐transplant erythrocytosis among adult kidney transplant recipients: a systematic review and meta‐analysis

et al. 2021

View full text Add to dashboard Cite

Post-transplant erythrocytosis (PTE) can occur in up to 10-16% after kidney transplant (KT). However, the post-transplant outcomes of recipients with PTE in the literature were conflicting. We performed systematic review and meta-analysis of published studies to evaluate risk factors of PTE as well as outcomes of recipients who developed PTE compared with controls. A literature search was conducted evaluating all literature from existence through February 2, 2021, using MEDLINE and EMBASE. Data from each study were combined using the random-effects model. (PROS-PERO: CRD42021230377). Thirty-nine studies from July 1982 to January 2021 were included (7,099 KT recipients). The following factors were associated with PTE development: male gender (pooled RR = 1.62 [1.38, 1.91], I 2 = 39%), deceased-donor KT (pooled RR = 1.18 [1.03, 1.35], I 2 = 32%), history of smoking (pooled RR = 1.36 [1.11, 1.67], I 2 = 13%), underlying polycystic kidney disease (PKD) (pooled RR=1.56 [1.21,2.01], I 2 =44%), and pretransplant dialysis (pooled RR=1.6 [1.02, 2.51], I 2 =46%). However, PTE was not associated with outcomes of interest, including overall mortality, death-censored graft failure, and thromboembolism. Our metaanalysis demonstrates that male gender, deceased-donor KT, history of smoking, underlying PKD, and pretransplant dialysis were significantly associated with developing PTE. However, with proper management, PTE has no impact on prognosis of KT patients.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Risk factors and outcomes of post‐transplant erythrocytosis among adult kidney transplant recipients: a systematic review and meta‐analysis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The characteristics of patients in this study were found to be similar to the general demographic characteristics of other studies [ 10 – 12 ]. In our study, PTE was common particularly in men (90.7% male) similar to the literature [ 2 , 6 , 10 – 12 ].…”

Section: Discussionsupporting

confidence: 84%

Risk Factors for Erythrocytosis in Renal Transplantation: Is Ganciclovir Therapy One of Them?

Koçak

Bali

2022

Ann Transplant

Self Cite

View full text Add to dashboard Cite

Background The purpose of this study was to identify the prevalence and risk factors of post-transplant erythrocytosis (PTE) and its relationship with cytomegalovirus (CMV). Material/Methods The study consisted of patients who received a kidney allograft and followed-up in our nephrology transplantation clinic from 2000 to 2014. Patient age, sex, length of dialysis, etiology of end-stage kidney disease, date of transplantation, medications, types of donors, the development of PTE were recorded. Results Among 185 adult kidney recipients, 43 (23.2%) had PTE. The average time between transplantation and diagnosis was 36 months. PTE was more common in male patients ( P <0.05) and patients with living donors and those who had been treated with ganciclovir after transplantation ( P <0.05). There were 79 patients treated for CMV – 54 in the non-PTE group and 24 in the PTE group. There was no significant difference in patient age, etiology of end-stage kidney disease, and immunosuppressive therapy when comparing the PTE group and non-PTE group. Univariate analysis showed ganciclovir therapy was significantly associated with PTE. However, this was not seen in the multivariate analyses. Conclusions Treatment with ganciclovir can precipitate development of PTE. Prospective studies are needed to assess the association of between PTE and CMV infection, valganciclovir, and ganciclovir.

show abstract

Prevalence of Erythrocytosis and Associated Clinical Manifestations in Renal Transplant Recipients

Sadiq,

Manzoor,

Riaz

et al. 2023

EJMED

View full text Add to dashboard Cite

Erythrocytosis, also known as polycythemia is commonly defined as increase in red blood cells (RBCs) or hemoglobin concentration in the body. Polycythemia can cause blood clots and increases the risk of life threatening thromboembolic complications such as, pulmonary embolism, stroke, deep vein thrombosis (DVT), and heart attack. PTE is frequently seen among renal transplant recipients with an incidence of 10-15%, however, higher prevalence has been recorded in other communities worldwide. Risk factors associated with PTE development include male gender, renal artery stenosis, retained native kidney, hypertension, hydronephrosis, and diabetes. Role of sex hormones, smoking, polycystic kidney disease, inhibition of renin -angiotensin aldosterone system, and excessive use of immunosuppressive medications, mainly containing mycophenolic acid derivate, have been well documented. Onset of erythrocytosis is usually seen by 8 to 24 months in well- functioning grafts. In some patients it resolves spontaneously, whereas in others, can persist for more than two years. Common clinical symptoms associated with PTE are headache, vision problem, lethargy, dizziness, plethora, and increased risk of thromboembolic phenomena, including deep venous thrombosis (DVT), stroke, myocardial infarction (MI), though some patients remained asymptomatic. To study this a retrospective single-center study was conducted at Pakistan Kidney and Liver Institute & Research Centre. Our study showed that out of a total population of 80 recipients, 31.2% of patients (n=25) developed PTE while 68.8% of patients (n=55) did not develop PTE. We also found that in 60% of the patients (n=15), polycythemia resolved within 6 months. It was also found that male gender was at increased risk of erythrocytosis, indicating strong association (p=0.02). Our study did not show any co-relationship between PTE and other predisposing factors as previously reported. A larger trial with prospective analysis is needed to find any significant association.

show abstract

Untitled

Cited by 3 publications

References 21 publications

Risk factors and outcomes of post‐transplant erythrocytosis among adult kidney transplant recipients: a systematic review and meta‐analysis

Risk factors and outcomes of post‐transplant erythrocytosis among adult kidney transplant recipients: a systematic review and meta‐analysis

Risk Factors for Erythrocytosis in Renal Transplantation: Is Ganciclovir Therapy One of Them?

Prevalence of Erythrocytosis and Associated Clinical Manifestations in Renal Transplant Recipients

Contact Info

Product

Resources

About